SK chemicals said Wednesday that they have launched Nose-R Soft Cap (fexofenadine), a third-generation antihistamine-based drug for allergic rhinitis.Nose-R is available at pharmacies without a prescription and is effective in relieving symptoms of allergic rhinitis caused by pollen and house dust,
Samsung C&T and its subsidiaries Samsung BioLogics and Samsung Bioepis said Tuesday that they have signed a memorandum of understanding for strategic cooperation with Flagship Pioneering in the United States through the Life Science Fund No. 2 (SVIC No. 64 New Technology Investment Fund) established
Celltrion said Wednesday that it has applied to the U.S. Food and Drug Administration (FDA) for securing interchangeability between CT-P17 (adalimumab) and its original drug, AbbVie’s Humira, for treating autoimmune diseases.Celltrion's application for the interchangeability of CT-P17 (Yuflyma in br
SAN FRANCISCO, Calif.— By Lee Han-soo, Korea Biomedical Review correspondent -- Yuhan Corp. aims to catch the eye of foreign investors and potential drug development partners at the J.P. Morgan Healthcare Conference (JPMHC) 2024 by unveiling its ambitious drive to become one of the top 50 global pha
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent –- Kakao Healthcare CEO Hwang Hee took the stage at the J.P. Morgan Healthcare Conference (JPMHC) 2024 in San Francisco, Calif., on Tuesday, unveiling ambitious plans for PASTA, its new mobile-based blood sugar management
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent -- At the J.P. Morgan Healthcare Conference (JPMHC) 2024 being held in San Francisco from Monday to Thursday, Samsung Biologics presented a detailed overview of its strategic vision and accomplishments.Samsung Biologics CE
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – Lotte Biologics, under the leadership of CEO Richard Lee, has once again made a notable appearance at the 42nd annual JPMorgan Healthcare Conference (JPMHC) on Tuesday.The JPMHC is ongoing in San Francisco from Monday to
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent –Flagship Pioneering, a company specializing in bioplatform innovation, and Samsung have announced a collaboration to enhance biopharmaceutical innovation on Monday. This partnership aims to utilize advanced technologies i
KoBioLabs, a Kosdaq-listed microbiome drug development company, said Tuesday that it has been granted a U.S. patent for KBL982 (roseburia intestinalis), a strain to treat obesity.KoBioLabs said that KBL982 is believed to reduce liver fat accumulation while restoring the imbalance of the gut microbio
Ajou University Hospital introduced the radiation therapy equipment, Halcyon 4.0 HyperSight, for the first time in Asia and began full-scale operation on Monday.Halcyon is a state-of-the-art radiotherapy equipment that performs optimal three-dimensional intensity-modulated rotational treatment in re
JLK, a Kosdaq-listed company that provides brain image AI analysis solutions, said Tuesday that it aims to achieve annual sales of 600 billion won ($456.5 million) by 2028 by boosting its AI services within the U.S. market.JLK has 11 products, including JBS-04K, a brain hemorrhage detection solution
Korean medical researchers have discovered a biomarker to detect Alzheimer's disease in tears.A research team -- led by Professor Ji Yong-woo of the Department of Ophthalmology at Yongin Severance Hospital and Professor Haam Seung-joo of the Department of Chemical and Biomedical Engineering at Yonse
For Korean bio clusters to succeed, they should strive to build industry-academia-research partnerships based on excellent human resources, as the biotech hub in Boston in the U.S. did, an expert said in a report.The Korea Healthcare Industry Development Institute (KHIDI) said so in its report, "Bos
If medical institutions must establish personal medical data transmission systems under the revised Medical Service Act, the government should directly or indirectly support the cost, a parliamentary report said.More specifically, based on the financial industry's use of financial data that has alre
Myongji Hospital has recruited Professor Park Joong-won of the National Cancer Center, an authority on liver cancer treatment who has identified the effectiveness of radiation (proton) therapy "for the first time worldwide."Professor Park, who started treatment at the Gastroenterology Department in
Seoul National University Bundang Hospital (SNUBH) has announced the release of its 2023 Outcomes Book 6th Edition.Every year, SNUBH publishes the Outcomes Book, which contains data on the status and quality of treatment by disease, the latest treatment trends, and innovative activities at the hospi
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – The J.P. Morgan Healthcare Conference kicked off its 42nd annual conference at the Westin St. Francis San Francisco on Monday, with investors attending the event showing a lot of excitement about the prospect of a revita
There is a rare, inherited disorder that causes excessive copper buildup in the liver. Its name is Wilson's disease -- an autosomal recessive genetic disorder that has a 25 percent chance of being passed on to children if both parents are carriers of a mutation in the ATP7B gene, even if neither par
On Friday, Samsung Pharm said it has submitted an application to the Ministry of Food and Drug Safety (MFDS) seeking approval to modify the investigational new drug (IND) plan for the phase 3 clinical trial of its Alzheimer's treatment, GV1001.The amended protocol is designed to test the superiority
Korean medical researchers have found a genetic link between educational attainment and genetics in East Asians.On Monday, a team of researchers, led by Professor Won Hong-hee and research fellow Kim Jae-young at Samsung Advanced Institute for Health Sciences and Technology (SAIHST) and Professor My